Revivent TC System is used to remove scar tissue on the left ventricle. Credit: Patrick J Lynch, medical illustrator.

US-based a privately held medical device company BioVentrix has secured Breakthrough Device Designation status from the US Food and Drug Administration (FDA) for its Revivent TC  Transcatheter Ventricular Enhancement System to treat heart failure.

For the Less Invasive Ventricular Enhancement (LIVE)  procedure, Revivent TC System is used to remove scar tissue on the left ventricle due to heart attack to enable efficient functioning of the healthy part of the heart.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The implanted micro-anchors are designed to bring back the heart to a more normal shape and size, minimising wall stress to boost blood flow across the body.

Drexel University College of Medicine cardiothoracic surgery department emeritus professor Andrew Wechsler said: “Heart failure continues to be an epidemic and the BioVentrix technology addresses a potentially curable cause of heart failure, which is precipitated by scarring of the left ventricle from a prior heart attack.

“Current methods for surgical remodelling of the ventricle are effective but highly invasive, and not well tolerated by patients. Having a less invasive method to treat the ventricle enables more patients to benefit from a more efficient heart.”

Currently, the ALIVE Trial of the Revivent TC System is enrolling up to 120 patients at up to 20 locations in the US. This trial has a primary endpoint analysis at one year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This system has secured the CE Mark and is now available in Europe.

BioVentrix CEO Ken Miller said: “The breakthrough designation for the Revivent TC System recognizes that many patients suffering from heart failure are at risk of death without a less invasive way to address their left ventricular damage.

“Being part of the Breakthrough Devices Program should help to speed the FDA’s evaluation and ultimately, market-entry, so more patients can be helped more quickly.”